JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
GlobeNewswire
*Ad hoc announcement pursuant to Art. 53 LR*
· Idorsia receives a positive opinion from the Committee for Medicinal..
*Ad hoc announcement pursuant to Art. 53 LR*
· Idorsia receives a positive opinion from the Committee for Medicinal..
BEIJING, April 25, 2024 /PRNewswire/ -- TAL Education Group (NYSE: TAL) ("TAL" or the "Company"), a smart learning solutions..
– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation –
– Additional data..